Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.

Hamzah L, Williams D, Bailey AC, Jones R, Ibrahim F, Musso CG, Burling K, Barbini B, Campbell L, Post FA; Fanconi-Tenofovir Alafenamide trial team.

HIV Med. 2019 Nov 3. doi: 10.1111/hiv.12819. [Epub ahead of print]

PMID:
31679186
2.

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.

Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR.

Clin Infect Dis. 2019 Oct 14. pii: ciz999. doi: 10.1093/cid/ciz999. [Epub ahead of print]

PMID:
31606734
3.

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.

Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M; EMERALD study group.

Antiviral Res. 2019 Oct;170:104543. doi: 10.1016/j.antiviral.2019.104543. Epub 2019 Jul 4.

4.

Cause of death among HIV patients in London in 2016.

Croxford S, Miller RF, Post FA, Harding R, Lucas SB, Figueroa J, Harrison I, Delpech VC, Dhoot S, Sullivan AK.

HIV Med. 2019 Oct;20(9):628-633. doi: 10.1111/hiv.12761. Epub 2019 Jul 5.

PMID:
31274241
5.

Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV.

De Francesco D, Underwood J, Bagkeris E, Anderson J, Williams I, Vera JH, Post FA, Boffito M, Johnson M, Mallon PWG, Winston A, Sabin CA; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study.

AIDS. 2019 Oct 1;33(12):1871-1880. doi: 10.1097/QAD.0000000000002293.

PMID:
31259766
6.

Cervical cancer risk in women living with HIV across four continents: A multicohort study.

Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, Taghavi K, Moore RD, Goedert JJ, Gill MJ, Silverberg MJ, D'Souza G, Patel P, Castilho JL, Ross J, Sohn A, Bani-Sadr F, Taylor N, Paparizos V, Bonnet F, Verbon A, Vehreschild JJ, Post FA, Sabin C, Mocroft A, Dronda F, Obel N, Grabar S, Spagnuolo V, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Hasse B, Konopnicki D, Roca B, Barger D, Clifford GM, Franceschi S, Egger M, Bohlius J.

Int J Cancer. 2020 Feb 1;146(3):601-609. doi: 10.1002/ijc.32260. Epub 2019 Jun 19.

PMID:
31215037
7.

Towards person-centred care for people living with HIV: what core outcomes matter, and how might we assess them? A cross-national multi-centre qualitative study with key stakeholders.

Bristowe K, Clift P, James R, Josh J, Platt M, Whetham J, Nixon E, Post FA, McQuillan K, Ní Cheallaigh C, Murtagh F, Anderson J, Sullivan AK, Harding R.

HIV Med. 2019 Sep;20(8):542-554. doi: 10.1111/hiv.12758. Epub 2019 Jun 4.

PMID:
31162817
8.

Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals.

De Francesco D, Winston A, Underwood J, Cresswell FV, Anderson J, Post FA, Williams I, Mallon PW, Sachikonye M, Babalis D, Vera JH, Bagkeris E, Milinkovic A, Sabin CA.

Int J STD AIDS. 2019 Apr;30(5):440-446. doi: 10.1177/0956462418817612. Epub 2019 Jan 10.

PMID:
30999830
9.

Kidney disease in Africans with HIV and tuberculosis.

Wearne N, Hung R, Bohmer R, Spies R, Omar A, Ash S, Ibrahim F, Miller RF, Booth JW, Lucas SB, Post FA.

AIDS. 2019 Jun 1;33(7):1207-1213. doi: 10.1097/QAD.0000000000002204.

PMID:
30932966
10.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M.

AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.

11.

Level of agreement between frequently used cardiovascular risk calculators in people living with HIV.

Dhillon S, Sabin CA, Alagaratnam J, Bagkeris E, Post FA, Boffito M, Anderson J, Vera J, Williams I, Johnson M, Sachikonye M, Babalis D, Mallon PW, Winston A; Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study.

HIV Med. 2019 May;20(5):347-352. doi: 10.1111/hiv.12731. Epub 2019 Mar 14.

12.

Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls.

De Francesco D, Underwood J, Bagkeris E, Boffito M, Post FA, Mallon P, Vera JH, Williams I, Anderson J, Johnson M, Sabin CA, Winston A; Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study.

HIV Med. 2019 Apr;20(4):274-285. doi: 10.1111/hiv.12714. Epub 2019 Feb 8.

13.

Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.

Halloran MO, Boyle C, Kehoe B, Bagkeris E, Mallon P, Post FA, Vera J, Williams I, Anderson J, Winston A, Sachikonye M, Sabin C, Boffito M.

Antivir Ther. 2019;24(3):193-201. doi: 10.3851/IMP3293.

PMID:
30700636
14.

Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study.

Whitworth HS, Badhan A, Boakye AA, Takwoingi Y, Rees-Roberts M, Partlett C, Lambie H, Innes J, Cooke G, Lipman M, Conlon C, Macallan D, Chua F, Post FA, Wiselka M, Woltmann G, Deeks JJ, Kon OM, Lalvani A; Interferon-γ Release Assays for Diagnostic Evaluation of Active Tuberculosis study group.

Lancet Infect Dis. 2019 Feb;19(2):193-202. doi: 10.1016/S1473-3099(18)30613-3. Epub 2019 Jan 14. Erratum in: Lancet Infect Dis. 2019 Feb;19(2):e39. Lancet Infect Dis. 2019 Mar;19(3):e64.

15.

High-risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV-positive men who have sex with men.

Pool E, Winston A, Bagkeris E, Vera JH, Mallon P, Sachikonye M, Post FA, Pozniak A, Boffito M, Anderson J, Williams I, Johnson M, Burgess L, Sabin CA; Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study team.

HIV Med. 2019 Feb;20(2):131-136. doi: 10.1111/hiv.12690. Epub 2018 Dec 12.

16.

Optimizing antiretroviral regimens in chronic kidney disease.

Hamzah L, Jones R, Post FA.

Curr Opin Infect Dis. 2019 Feb;32(1):1-7. doi: 10.1097/QCO.0000000000000509.

PMID:
30461453
17.

Pain in people living with HIV and its association with healthcare resource use, well being and functional status.

Sabin CA, Harding R, Bagkeris E, Nkhoma K, Post FA, Sachikonye M, Boffito M, Anderson J, Mallon PWG, Williams I, Vera J, Johnson M, Babalis D, Winston A.

AIDS. 2018 Nov 28;32(18):2697-2706. doi: 10.1097/QAD.0000000000002021.

PMID:
30289809
18.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.

Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, Post FA, Morales-Ramirez J, Thompson M, Osiyemi O, Rashbaum B, Stellbrink HJ, Martorell C, Liu H, Liu YP, Porter D, Collins SE, SenGupta D, Das M.

HIV Med. 2018 Nov;19(10):724-733. doi: 10.1111/hiv.12664. Epub 2018 Aug 12.

19.

Chronic Kidney Disease Risk in African and Caribbean Populations With HIV.

Jose S, Hamzah L, Jones R, Williams D, Winston A, Burns F, Phillips AN, Sabin CA, Post FA; UK CHIC Study.

J Infect Dis. 2018 Oct 20;218(11):1767-1772. doi: 10.1093/infdis/jiy397.

20.

Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study.

Bagkeris E, Burgess L, Mallon PW, Post FA, Boffito M, Sachikonye M, Anderson J, Asboe D, Garvey L, Vera J, Williams I, Johnson M, Babalis D, De Francesco D, Winston A, Sabin CA.

Int J Epidemiol. 2018 Oct 1;47(5):1391-1392e. doi: 10.1093/ije/dyy072. No abstract available.

21.

Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America.

Caro-Vega Y, Schultze A, W Efsen AM, Post FA, Panteleev A, Skrahin A, Miro JM, Girardi E, Podlekareva DN, Lundgren JD, Sierra-Madero J, Toibaro J, Andrade-Villanueva J, Tetradov S, Fehr J, Caylà J, Losso MH, Miller RF, Mocroft A, Kirk O, Crabtree-Ramírez B.

BMC Infect Dis. 2018 Apr 23;18(1):191. doi: 10.1186/s12879-018-3077-x.

22.

Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.

Post FA, Szubert AJ, Prendergast AJ, Johnston V, Lyall H, Fitzgerald F, Musiime V, Musoro G, Chepkorir P, Agutu C, Mallewa J, Rajapakse C, Wilkes H, Hakim J, Mugyenyi P, Walker AS, Gibb DM, Pett SL; Reduction of EArly mortaLITY in HIV-infected adults and children starting antiretroviral therapy (REALITY) Trial Team.

Clin Infect Dis. 2018 Mar 4;66(suppl_2):S132-S139. doi: 10.1093/cid/cix1141.

23.

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.

Winston A, Post FA, DeJesus E, Podzamczer D, Di Perri G, Estrada V, Raffi F, Ruane P, Peyrani P, Crofoot G, Mallon PWG, Castelli F, Yan M, Cox S, Das M, Cheng A, Rhee MS.

Lancet HIV. 2018 Apr;5(4):e162-e171. doi: 10.1016/S2352-3018(18)30010-9. Epub 2018 Feb 20.

24.

Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals.

Mora-Peris B, Bouliotis G, Ranjababu K, Clarke A, Post FA, Nelson M, Burgess L, Tiraboschi J, Khoo S, Taylor S, Ashby D, Winston A.

AIDS. 2018 May 15;32(8):1007-1015. doi: 10.1097/QAD.0000000000001786.

25.

Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, Post FA, Wearne N, Winkler CA, Cheung M, Wheeler DC, Winkelmayer WC, Wyatt CM; Conference Participants.

Kidney Int. 2018 Mar;93(3):545-559. doi: 10.1016/j.kint.2017.11.007. Epub 2018 Feb 3.

26.

Promoting high standards of care for women living with HIV: position statement from the Women Against Viruses in Europe Working Group.

Kowalska JD, Aebi-Popp K, Loutfy M, Post FA, Perez-Elias MJ, Johnson M, Mulcahy F; Women Against Viruses in Europe (WAVE) Working Group.

HIV Med. 2018 Feb;19(2):167-173. doi: 10.1111/hiv.12565. Epub 2017 Nov 21. Review.

PMID:
29159861
27.

Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study.

Efsen AMW, Schultze A, Miller RF, Panteleev A, Skrahin A, Podlekareva DN, Miro JM, Girardi E, Furrer H, Losso MH, Toibaro J, Caylà JA, Mocroft A, Lundgren JD, Post FA, Kirk O; TB: HIV study in EuroCoord.

J Infect. 2018 Jan;76(1):44-54. doi: 10.1016/j.jinf.2017.10.007. Epub 2017 Oct 20.

28.

Evaluating the Impact of Functional Genetic Variation on HIV-1 Control.

McLaren PJ, Pulit SL, Gurdasani D, Bartha I, Shea PR, Pomilla C, Gupta N, Gkrania-Klotsas E, Young EH, Bannert N, Del Amo J, Gill MJ, Gilmour J, Kellam P, Kelleher AD, Sönnerborg A, Zangerle R, Post FA, Fisher M, Haas DW, Walker BD, Porter K, Goldstein DB, Sandhu MS, de Bakker PIW, Fellay J.

J Infect Dis. 2017 Nov 27;216(9):1063-1069. doi: 10.1093/infdis/jix470. Erratum in: J Infect Dis. 2018 Jun 5;218(1):171.

29.

Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls.

Kooij KW, Vogt L, Wit FWNM, van der Valk M, van Zoest RA, Goorhuis A, Prins M, Post FA, Reiss P; AGEhIV Cohort Study.

J Infect Dis. 2017 Sep 15;216(6):622-631. doi: 10.1093/infdis/jix202. Erratum in: J Infect Dis. 2018 Apr 23;217(10):1673.

PMID:
28934420
30.

The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.

Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM, Post FA, Hill T, Kirk O, Pozniak A, Nelson M, Tostevin A, Dunn D, Lundgren J, Cozzi-Lepri A.

Antivir Ther. 2018;23(2):105-116. doi: 10.3851/IMP3178.

PMID:
28627486
31.

Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.

O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, Dunn D, Winston A, Post FA, Sabin C, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study.

Lancet HIV. 2017 Jul;4(7):e295-e302. doi: 10.1016/S2352-3018(17)30053-X. Epub 2017 May 4.

32.

Kidney transplant outcomes in HIV serodiscordant recipient pairs.

Gathogo EN, Shah S, Post FA.

AIDS. 2017 May 15;31(8):1199-1201. doi: 10.1097/QAD.0000000000001457. No abstract available.

PMID:
28441179
33.

Alemtuzumab induction therapy in HIV-positive renal transplant recipients.

Mclean FE, Gathogo E, Goodall D, Jones R, Kinloch S, Post FA.

AIDS. 2017 Apr 24;31(7):1047-1048. doi: 10.1097/QAD.0000000000001413. No abstract available.

PMID:
28350580
34.

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>.

Post FA, Yazdanpanah Y, Schembri G, Lazzarin A, Reynes J, Maggiolo F, Yan M, Abram ME, Tran-Muchowski C, Cheng A, Rhee MS.

HIV Clin Trials. 2017 May;18(3):135-140. doi: 10.1080/15284336.2017.1291867. Epub 2017 Mar 17.

PMID:
28303753
35.

Successful pregnancy in an HIV-positive kidney transplant recipient.

Mahalingasivam V, Gathogo E, Bramham K, Post FA.

AIDS. 2017 Mar 27;31(6):872-873. doi: 10.1097/QAD.0000000000001403. No abstract available.

PMID:
28272141
36.

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Martorell CT, de Wet J, Stellbrink HJ, Molina JM, Post FA, Valero IP, Porter D, Liu Y, Cheng A, Quirk E, SenGupta D, Cao H.

Lancet HIV. 2017 May;4(5):e205-e213. doi: 10.1016/S2352-3018(17)30032-2. Epub 2017 Mar 2.

PMID:
28259776
37.

Bone mineral density decline in patients on stable antiretroviral therapy.

Post FA.

AIDS. 2017 Mar 13;31(5):727-729. doi: 10.1097/QAD.0000000000001396. No abstract available.

PMID:
28225451
38.

Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.

Hamzah L, Jose S, Booth JW, Hegazi A, Rayment M, Bailey A, Williams DI, Hendry BM, Hay P, Jones R, Levy JB, Chadwick DR, Johnson M, Sabin CA, Post FA.

J Infect. 2017 May;74(5):492-500. doi: 10.1016/j.jinf.2017.01.010. Epub 2017 Jan 25.

39.

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.

Jose S, Nelson M, Phillips A, Chadwick D, Trevelion R, Jones R, Williams DI, Hamzah L, Sabin CA, Post FA; UK CHIC study.

AIDS. 2017 Feb 20;31(4):485-492. doi: 10.1097/QAD.0000000000001353.

40.

Tenofovir disoproxil fumarate-associated bone loss: does vitamin D-binding protein play a role?

Post FA, Hamzah L, Fox J.

AIDS. 2017 Jan 2;31(1):178-179. No abstract available.

PMID:
27898597
41.

Managing chronic kidney disease in the older adults living with HIV.

Post FA.

Curr Opin Infect Dis. 2017 Feb;30(1):4-11. doi: 10.1097/QCO.0000000000000333. Review.

PMID:
27828808
42.

Defining cognitive impairment in people-living-with-HIV: the POPPY study.

De Francesco D, Underwood J, Post FA, Vera JH, Williams I, Boffito M, Sachikonye M, Anderson J, Mallon PW, Winston A, Sabin CA; POPPY study group.

BMC Infect Dis. 2016 Oct 28;16(1):617.

43.

Associations between cognitive impairment and patient-reported measures of physical/mental functioning in older people living with HIV.

Underwood J, De Francesco D, Post FA, Vera JH, Williams I, Boffito M, Mallon PW, Anderson J, Sachikonye M, Sabin C, Winston A; Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study group.

HIV Med. 2017 May;18(5):363-369. doi: 10.1111/hiv.12434. Epub 2016 Oct 26.

44.

Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):180-184. doi: 10.1097/QAI.0000000000001186.

45.

Pellagra: a rare complication of isoniazid therapy.

Post FA.

Int J Tuberc Lung Dis. 2016 Aug;20(8):1136. doi: 10.55888/ijtld.16.0352. No abstract available.

PMID:
27393553
46.

Monitoring of kidney function in older people living with HIV.

Post FA, Yombi JC, Hougardy JM.

HIV Med. 2018 Feb;19(2):e51. doi: 10.1111/hiv.12396. Epub 2016 Jul 6. No abstract available.

PMID:
27385465
47.

Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.

Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Miro JM, Vassilenko A, Girardi E, Bruyand M, Obel N, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord.

Lancet HIV. 2016 Mar;3(3):e120-31. doi: 10.1016/S2352-3018(15)00252-0. Epub 2016 Feb 2.

PMID:
26939735
48.

Clinical characteristics and outcomes of HIV-associated immune complex kidney disease.

Booth JW, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar EA, Turner-Stokes T, Khatib N, Das P, Naftalin C, Mackie N, Kingdon E, Williams D, Hendry BM, Sabin C, Jones R, Levy J, Hilton R, Connolly J, Post FA; HIV/CKD Study and the UK CHIC Study.

Nephrol Dial Transplant. 2016 Dec;31(12):2099-2107. Epub 2016 Jan 18.

PMID:
26786550
49.

Should kidney disease risk affect antiretroviral choice?

Post FA.

Lancet HIV. 2016 Jan;3(1):e3-5. doi: 10.1016/S2352-3018(15)00213-1. Epub 2015 Nov 17. No abstract available.

PMID:
26762991
50.

Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America.

Efsen AM, Schultze A, Post FA, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Skrahin A, Miro JM, Caylà JA, Girardi E, Bruyand M, Obel N, Podlekareva DN, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord.

PLoS One. 2015 Dec 30;10(12):e0145380. doi: 10.1371/journal.pone.0145380. eCollection 2015.

Supplemental Content

Support Center